Table 1 Diagnostic sensitivity of TBLC for each disease.

From: Sensitivity of transbronchial lung cryobiopsy in the diagnosis of different interstitial lung diseases

MDD diagnosis

Sensitivity without C/R (n = 431)

Sensitivity with C/R (n = 213)

n (%)

P value

n (%)

P value

IIP

95/146 (65.1%)

 

50/62 (80.7%)

 

IPF

77/106 (72.6%)

 

43/50 (86.0%)

 

Idiopathic NSIP

0/6 (0.0%)

 < 0.001*

0/2 (0.0%)

0.027*

COP

7/12 (58.3%)

0.323*

1/1 (100%)

1.000*

SR-ILD

7/17 (41.2%)

0.022*

4/7 (57.1%)

0.095*

HP

50/88 (56.8%)

0.215**

42/52 (80.8%)

1.000**

Fibrotic HP

34/67 (50.8%)

0.009*

30/37 (81.1%)

0.567*

Non-fibrotic HP

16/21 (76.2%)

1.000*

12/15 (80.0%)

0.685*

Iatrogenic

9/14 (64.3%)

1.000**

2/5 (40.0%)

0.070**

Drug induced ILD

9/12 (75.0%)

1.000*

2/4 (50.0%)

0.125*

Radiation pneumonitis

0/2 (0.0%)

0.081*

0/1 (0.0%)

0.157*

CTD-ILD

24/54 (44.4%)

0.010**

29/33 (87.9%)

0.566**

RA

10/21 (47.6%)

0.038*

11/12 (91.7%)

1.000*

Sjogren syndrome

2/8 (25.0%)

0.010*

4/5 (80.0%)

0.559*

SSc

2/8 (25.0%)

0.010*

5/6 (83.3%)

1.000*

PM/DM

4/6 (66.7%)

0.668*

5/5 (100%)

1.000*

AAV

3/8 (37.5%)

0.050*

2/3 (66.7%)

0.394*

Other disease

39/57 (68.4%)

0.742**

15/17 (88.2%)

0.722**

Sarcoidosis

8/11 (72.7%)

1.000*

3/4 (75.0%)

0.484*

Infection

6/10 (60.0%)

0.467*

0/1 (0.0%)

0.157*

Pneumoconiosis

2/4 (50.0%)

0.315*

1/1 (100%)

1.000*

Unclassifiable ILD

14/72 (19.4%)

 < 0.001**

9/35(20.5%)

 < 0.001**

  1. Significant values are in bold.
  2. AAV, anti-neutrophil cytoplasmic antibody associated vasculitis; COP, cryptogenic organizing pneumonia; C/R, clinical/radiological information; CTD, connective tissue disease; HP, hypersensitivity pneumonitis; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; PM/DM, polymyiositis/dermatomyositis; RA, rheumatoid arthritis; SR-ILD, smoking related interstitial lung disease; SSc, systemic sclerosis.
  3. * Compared with IPF.
  4. ** Compared with IIPs.
Back to article page